Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$0.88
-8.5%		$0.89
$0.38
▼
$19.19
$37.77M1.042.05 million shs1.79 million shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$0.20
$0.20
$0.18
▼
$1.94
$9.52M1.573.75 million shsN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.33
+1.1%		$1.32
$0.85
▼
$2.23
$33.82M1.79533,018 shs80,413 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+1,712.46%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
+12.94%+47.01%+14.15%+68.42%-51.39%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%0.00%0.00%0.00%0.00%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-9.03%+3.97%+21.30%-13.25%-8.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$0.88
-8.5%		$0.89
$0.38
▼
$19.19
$37.77M1.042.05 million shs1.79 million shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$0.20
$0.20
$0.18
▼
$1.94
$9.52M1.573.75 million shsN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.33
+1.1%		$1.32
$0.85
▼
$2.23
$33.82M1.79533,018 shs80,413 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+1,712.46%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
+12.94%+47.01%+14.15%+68.42%-51.39%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%0.00%0.00%0.00%0.00%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-9.03%+3.97%+21.30%-13.25%-8.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00
N/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00
N/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.00
Buy$6.00352.83% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M11.05N/AN/A($2.06) per share-0.29
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$3.91M9.65N/AN/A$0.70 per share1.25
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-$3.08M-$0.43N/AN/AN/A-85.56%-63.93%-31.42%N/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.40N/AN/AN/AN/A-87.90%-78.69%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.69839.96%N/AN/A N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A

Latest EPIX, NNVC, CPHI, and ADXS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/1/2100
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
--$1.698/25/20258/19/20258/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.22
0.79
0.26
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
69.06
69.06
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
6.40%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2059.31 million42.36 millionNot Optionable
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
22143.02 million15.92 millionNot Optionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5047.31 million39.98 millionOptionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
725.53 million14.92 millionOptionable

Recent News About These Companies

NanoViricides (NYSE:NNVC) Shares Down 3.4% - Time to Sell?
October 7 at 1:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094303
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
October 6 at 8:45 AM  |  accessnewswire.comA
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over ...
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NNVC/pressreleases/4961335/nanoviricides-provides-additional-details-on-the-phase-ii-clinical-trial-of-nv-387-oral-gummies-as-a-treatment-for-ebola-as-the-outbreak-continues-to-expand-and-has-taken-over-4000-lives/
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
October 5, 2026  |  accessnewswire.comA
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricides
September 29, 2026  |  marketscreener.comM
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
September 29, 2026  |  accessnewswire.comA
NanoViricides: Fiscal Q4 Earnings Snapshot
September 28, 2026  |  khou.comK
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
September 28, 2026  |  accessnewswire.comA
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
September 23, 2026  |  accessnewswire.comA
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48 ...
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/clinical-trial-oral-drug-nv-132500733.html
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
September 15, 2026  |  accessnewswire.comA
Ebola Clinical Trial for Oral Drug NV-387 Registered in DRC
September 8, 2026  |  desmoinesregister.comD
Ebola Oral Drug Trial NV-387 Registered in DRC for Outbreak
September 8, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/42555/ebola-oral-drug-trial-nv-387-registered-in-drc-for-outbreak/
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand ...
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/clinical-trial-oral-drug-treat-123000295.html
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
September 8, 2026  |  accessnewswire.comA
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 ...
August 31, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/41622/while-measles-cases-continue-to-increase-in-the-usa-and-globally-nanoviricides-is-getting-ready-for-clinical-trials-of-its-revolutionary-broad-spectrum-drug-candidate-nv-387-as-a-treatment-for-measle/
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
August 31, 2026  |  accessnewswire.comA
NanoViricides Inc
August 19, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/nnvc-nanoviricides-inc/vitals
NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
August 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69342159-nanoviricides-the-phase-ii-clinical-trial-of-nv-387-oral-gummies-as-a-treatment-for-ebola-in-dr-congo-to-fight-the-current-largest-ever-and-expanding-200.htm
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
August 18, 2026  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)
As of 10/8/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

China Pharma stock logo

China Pharma NYSE:CPHI

$0.88 -0.08 (-8.54%)
As of 02:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.32 +0.02 (+1.15%)
As of 02:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas